Introduction {#Sec1}
============

The pivotal milestone in the minimally invasive treatment of large kidney stones was firstly described by Fernstrom and Johansson, who performed stone removal procedures using percutaneous access \[[@CR1]\]. Percutaneous nephrolithotomy (PCNL) should be performed, according to the European Association of Urology (EUA) and American Urological Association (AUA) guidelines, in patients with renal calculi over 2 cm in diameter, irrespective of the location, and may also be utilized for lower pole stones over 1.5 cm \[[@CR2]--[@CR4]\]. In the classic percutaneous nephrolithotomy technique (cPCNL), the nephrostomy tube is used to allow access for the second-look procedure, to secure urinary drainage in the case of ureteral obstruction and to compress kidney parenchyma to stop bleeding from the surgical site \[[@CR2], [@CR5]--[@CR7]\]. In 1997, Bellman introduced the tubeless percutaneous nephrolithotomy (tPCNL) method, which is currently gaining more and more recognition among urologists \[[@CR2], [@CR8]\]. It seems that the advantage of tPCNL over cPCNL is associated primarily with a shorter hospitalization time, less pain and a significant reduction in the use of analgesics \[[@CR5]\]. PCNL leads to an increase in oxidative stress marker (OSM) concentrations (activity), which reflects a certain imbalance between released free radicals from tissues and the antioxidant capacity of the environment \[[@CR9]--[@CR11]\]. Our primary goal was to compare cPCNL and tPCNL in terms of OSMs concentrations. The secondary aim was to find any factors that might influence OSMs after PCNL.

Patients and methods {#Sec2}
====================

Inclusion and exclusion criteria {#Sec3}
--------------------------------

The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. The study was conducted between September 2016 and May 2018. Seventy-two patients who underwent PCNL procedure at our department were enrolled in the study. The first group consisted of 33 patients where cPCNL with nephrostomy tube after operation was utilized. The second group comprised 39 patients where tubeless PCNL was applied.

Inclusion criteria consisted of:

Patients with stone over 2 cm in diameter in a kidneyPatients with stones 1--2 cm who wished to have PCNL instead of retrograde intrarenal surgery or shockwave lithotripsy (SWL)Patients with stones 1--2 cm with contraindications for SWL

Exclusion criteria consisted of:

Residual stones after surgery and need for a second lookDouble-J stent or nephrostomy catheter inserted preoperativelyPersistent bacteriuria despite antibiotic therapy before operationBleeding diathesisSolitary kidneyUreteral obstructionProlonged procedure (more than 3 h)Intraoperative difficulties or complicationsSevere bleeding

Classic and tubeless PCNL {#Sec4}
-------------------------

All patients qualified for PCNL had contrast-enhanced computed tomography performed before surgery. All patients are admitted to hospital 2 days before surgery for additional consultations, imaging (ultrasound and X-ray), blood and urine tests. Two kinds of PCNL were utilized: classic (with nephrostomy tube)---the first group, and tubeless---the second group. Briefly, we operate patients in prone position with utilization of Amplatz dilators and sheaths. Patients are operated in general anesthesia. Perioperatively second-generation cephalosporin is used as antibiotic prophylaxis. Puncture and tract formation are done by urologist under fluoroscopic guidance. We use 26 Fr nephroscope with ultrasound as well as pneumatic lithotripter to disintegrate the stone. At the end of PCNL, either reentry Malecot (16Fr) nephrostomy or TachoSil® was inserted into kidney \[[@CR12]--[@CR14]\]. TachoSil® is a kind of a patch and has two adherent layers. The outer layer is composed of fibrinogen and thrombin that promote coagulation process. The inner layer has a honeycomb structure and is composed of equine collagen. Platelets with coagulation factors form clot in the yellow layer that is surrounded and attached to kidney parenchyma on one side and equine collagen on the other side. Such mechanism of action ensures good hemostasis \[[@CR12]\]. There were no patients operated with totally tubeless technique in this study. Ureteral catheter (in tPCNL) was removed next day in the morning after operation. Reentry Malecot catheter was removed 2 days after operation. There was no formal randomization. Two senior urologists performed PCNL procedures in this study. The first one (P.B.) performed only tubeless, while the second one (A.P.) only classic procedures.

Measures {#Sec5}
--------

Blood and urine measures were taken perioperatively in each patient as in every PCNL procedure performed in our department. In addition, four samples (1 ml) of voided urine were collected every 24 h in the evening. The first sample was taken the day before operation. Samples were immediately frozen and stored in containers. Catalase (CAT) activity in urine was measured by method of Johansson and Borg \[[@CR15]\] using an automated analyzer PerkinElmer and expressed in IU/l urine \[[@CR15]\]. The urine protein sulfhydryl groups (SH) concentration was determined as described by Koster et al. \[[@CR16]\] using an automated PerkinElmer analyzer and expressed in µmol/l \[[@CR16]\]. Total antioxidant capacity (TAC) in urine was measured according to Erel \[[@CR17]\] using an automated PerkinElmer analyzer and expressed in mmol/l \[[@CR17]\]. Determination of superoxide dismutase (SOD) activity was done by the method of Oyanagui \[[@CR18]\]. The activity of SOD is equal to one nitric unit (NU) when it inhibits nitric ion production by 50%. Activity of SOD was expressed in NU/ml of urine \[[@CR18]\].

Statistical analysis {#Sec6}
--------------------

The distributions of oxidative stress parameters were not normal; thus, logarithmic transformation of data was applied. However, for better visualization, means of absolute values were shown in the graphs. General linear model with analysis of covariance with repeated measures and post hoc analysis with Tukey test was utilized to seek for any differences in OSM, hemoglobin and protein concentration in urine in respective days. For other continuous variables without normal distributions, Mann--Whitney *U* test was used. For categorical variables, Chi-square test was applied. Nonparametric correlations with Spearman test were applied to seek for any relation between dependant and independent and within dependant variables. Blood parameters with normal distribution were analyzed with *t* tests. Repeated measures with normal distribution were analyzed with Hotelling's test. A *p* values less than 0.05 were considered significant. Statistical analysis was conducted using Statistica Statsoft™ version 13.1.

Results {#Sec7}
=======

Preoperative characteristics of patients are given in Table [1](#Tab1){ref-type="table"}. As shown, there were no apparent differences between groups. In order to search for any relationship between continuous preoperative variables (like sodium, potassium, creatinine concentration) and OSM concentrations, we performed correlation tests, but there was no significance in any of them. Similarly, in order to exclude any bias, we compared preoperative continuous variables between categorical variables (i.e., sex, infracostal/intercostals access, uni-/multitract access, accessed calyx) but we also did not find any significance. Postoperative characteristics of our groups are given in Table [2](#Tab2){ref-type="table"}. Only hospitalization time was favorable for tPCNL. Table [3](#Tab3){ref-type="table"} shows the comparison of pre- and postoperative characteristics of analyzed groups.

Table 1Demographic and preoperative clinical characteristics of analyzed groupsClassic PCNL (*n* = 33)Tubeless PCNL (*n* = 39)*P* valueAge, year, median58530.56Sex, no. (%) Female20 (27.7)16 (22.2)0.1 Male13 (18)23 (31.9)BMI, kg/m^2^, mean (SD)29 (6)29.2 (4.8)0.8Hypertension, *n* (%) Yes18 (25)18 (25)0.47 No15 (20.8)21 (29.1)Diabetes, *n* (%) Yes7 (9.7)3 (4.17)0.18 No26 (36.1)36 (50)Sodium concentration, mmol/l, mean (SD)142.6 (2.3)141.9 (2.3)0.2Potassium concentration, mmol/l, mean (SD)4.4 (0.3)4.3 (0.3)0.3Creatinine concentration, µmol/l, mean (SD)81 (20.5)80.4 (17.4)0.9Hemoglobin, g/dl, mean (SD)14.5 (1.3)14.8 (1.6)0.29White blood cells, n/mcl, mean (SD)8.6 (2.2)7.9 (1.9)0.18Platelet count, n/mcl, mean (SD)248.1 (49.1)256.4 (79.4)0.6Leukocyturia \> 5 per high power field, *n* (%) Yes20 (27.7)17 (23.6)0.15 No13 (18)22 (30.5)Side, *n* (%) Left19 (26.3)23 (31.9)0.9 Right14 (19.4)16 (22.2)Stone diameter, mm, mean (SD)28.9 (13.4)25.7 (12.9)0.3Stone position, *n* (%) Calyx7 (9.7)14 (19.4)0.24 Pelvis10 (13.8)13 (18) Staghorn16 (22.2)12 (16.6)

Table 2Postoperative characteristics of analyzed groupsClassic PCNL (*n* = 33)Tubeless PCNL (*n* = 39)*P* valueOperation time, min, mean (SD)109 (34.8)100 (34.2)0.2Access, *n* (%) Infracostal21 (29.1)26 (36.1)0.78 Intercostal12 (16.6)13 (18)Multitract access, *n* (%) Yes5 (6.9)3 (4.1)0.31 No28 (38.8)36 (50)Accessed calyx, *n* (%) Upper1 (1.3)00.46 Middle8 (11.1)11 (15.2) Lower19 (26.3)25 (34.7) Upper + middle + lower1 (1.3)1 (1.3) Upper + lower01 (1.3) Middle + lower4 (5.5)1 (1.39)Fever \> 38.5 °C^a^, *n* (%) Yes4 (5.5)6 (8.3)0.68 No29 (40.2)33 (45.8)Hospitalization time, days, median75\< 0.001^a^The first day after operation

Table 3Preoperative and postoperative characteristics of analyzed groupsPreoperatively*P* value^a^6 h after surgery*P* value^a^*P* value^b^cPCNL (*n* = 33)tPCNL (*n* = 39)cPCNL (*n* = 33)tPCNL (*n* = 39)Hemoglobin, g/dl, mean (SD)14.5 (1.37)14.8 (1.6)0.2912.5 (1.52)13.2 (1.66)0.070.17White blood cells, n/mcl, mean (SD)8.6 (2.2)7.9 (1.9)0.1812.4 (5.1)12 (4.6)0.720.31Platelet count, n/mcl, mean (SD)248.1 (49.1)256.4 (79.4)0.6201.8 (53.6)217.6 (68)0.20.41Creatinine µmol/l, mean (SD)81 (20.5)80.4 (17.4)0.984 (20)83.9 (18.4)0.90.99Sodium concentration, mmol/l, mean (SD)142.6 (2.3)141.9 (2.3)0.21140.3 (3.5)140.4 (2.92)0.840.4Potassium concentration, mmol/l, mean (SD)4.4 (0.3)4.3 (0.3)0.34.2 (0.5)4.2 (0.3)0.70.5^a^ *t* test^b^Hotelling's test

OSMs were positively (negatively for TAC) and significantly correlated with each other in respective days. Protein and hemoglobin concentrations in urine were positively and significantly correlated. Similarly CAT, SOD and SH were positively and significantly correlated with hemoglobin and protein concentration in urine. TAC was positively and significantly correlated with protein but not hemoglobin concentration in respective days. Of all OSMs, SOD had the highest correlation coefficient with hemoglobin and protein concentration (*r* = 0.8; *r* = 0.72 with *p* \< 0.05 at day 2, respectively).

In order to exclude the influence of protein and hemoglobin concentration on OSMs, analysis of covariance was utilized to test the pure oxidative stress effect of operation and nephrostomy tube. The differences in OSM concentrations between cPCNL and tPCNL are given in Table [4](#Tab4){ref-type="table"}. As shown only CAT and TAC concentrations were significantly favorable in tPCNL group in day 3 and 4. Figure [1](#Fig1){ref-type="fig"} represents means of OSM concentrations in respective days. Figure [2](#Fig2){ref-type="fig"} shows hemoglobin and protein concentration in urine in respective days. They all show that surgery itself triggers the highest stress effect at the day of PCNL (Table [5](#Tab5){ref-type="table"}).

Table 4Concentrations of oxidative stress markers in urineClassic PCNL (*n* = 33)Tubeless PCNL (*n* = 39)*P* valueDay 1 Protein, g/l, mean (SD)1.9 (1.3)2.4 (1.5)0.24 Hemoglobin, g/l, mean (SD)0.3 (0.1)0.3 (0.1)0.48 CAT, IU/l, mean (SD)19.4 (41.4)11.7 (9.6)0.86 SH, µmol/l, mean (SD)18 (52.6)58.7 (133.7)0.08 TAC, mmol/l, mean (SD)2.02 (0.08)1.99 (0.1)0.1 SOD, NU/ml, mean (SD)20.5 (12.3)22.6 (14.5)0.75Day 2 Protein, g/l, mean (SD)2.5 (1.8)3.1 (2.2)0.42 Hemoglobin, g/l, mean (SD)0.7 (0.7)0.7 (0.9)0.7 CAT, IU/l, mean (SD)89 (73.2)104.9 (84.6)0.42 SH, µmol/l, mean (SD)334.7 (459.2)518.9 (899.4)0.73 TAC, mmol/l, mean (SD)1.87 (0.2)1.79 (0.3)0.49 SOD, NU/ml, mean (SD)33.7 (25.1)41.4 (35.8)0.49Day 3 Protein, g/l, mean (SD)2.4 (1.8)3.1 (2)0.09 Hemoglobin, g/l, mean (SD)0.9 (1.3)0.5 (0.3)0.49 CAT, IU/l, mean (SD)67.4 (68.6)28.3 (26.5)0.04 SH, µmol/l, mean (SD)206.8 (473.1)306.9 (1018.7)0.91 TAC, mmol/l, mean (SD)2.01 (0.09)2.06 (0.07)0.04 SOD, NU/ml, mean (SD)38.2 (26.1)36.6 (26.3)0.75Day 4 Protein, g/l, mean (SD)2.9 (2.7)2.9 (2.5)0.59 Hemoglobin, g/l, mean (SD)0.6 (0.6)0.5 (0.4)0.87 CAT, IU/l, mean (SD)47.4 (67.6)18.5 (21.7)0.02 SH, µmol/l, mean (SD)129.3 (428.7)208.7 (929.1)0.33 TAC, mmol/l, mean (SD)2.00 (0.1)2.06 (0.03)\< 0.001 SOD, NU/ml, mean (SD)35 (30.3)45.2 (36)0.16

Fig. 1Oxidative stress markers activity in four consecutive days

Fig. 2Protein and hemoglobin concentration in four consecutive days

Table 5Post hoc tests for repeated measures in analyzed groupsClassic PCNL (*n* = 33)Tubeless PCNL (*n* = 39)CAT 1CAT 2CAT 3CAT 4CAT 1CAT 2CAT 3CAT 4CAT 1**0.0000320.000136**0.124724**0.000032**0.6667250.996615CAT 2**0.000032**0.429027**0.0016850.0000320.0000320.000032**CAT 3**0.000136**0.4290270.5404840.666725**0.000032**0.972063CAT 40.124724**0.001685**0.5404840.996615**0.000032**0.972063SH 1SH 2SH 3SH 4SH 1SH 2SH 3SH 4SH 1**0.031142**0.9054620.995153**0.021457**0.8499180.950017SH 2**0.031142**0.9887070.859574**0.021457**0.5602000.369050SH 30.9054620.9887070.9995290.8499180.5602000.999993SH 40.9951530.8595740.9995290.9500170.3690500.999993TAC 1TAC 2TAC 3TAC 4TAC 1TAC 2TAC 3TAC 4TAC 1**0.004384**0.9998520.999665**0.000038**0.6322440.562615TAC 2**0.0043840.0211100.0254660.0000380.0000320.000032**TAC 30.999852**0.021110**1.0000000.632244**0.000032**1.000000TAC 40.999665**0.025466**1.0000000.562615**0.000032**1.000000SOD 1SOD 2SOD 3SOD 4SOD 1SOD 2SOD 3SOD 4SOD 1**0.0247070.0003650.0082170.0000420.0043690.000032**SOD 2**0.024707**0.9567280.999983**0.000042**0.8975100.972115SOD 3**0.000365**0.9567280.994151**0.004369**0.8975100.281848SOD 4**0.008217**0.9999830.994151**0.000032**0.9721150.281848Significant differences are marked bold. CAT 1--4---catalase in days 1--4; SH 1--4---protein sulfhydryl groups in days 1--4; TAC 1--4---total antioxidant capacity in days 1--4; SOD 1--4---superoxide dismutase in days 1--4

Discussion {#Sec8}
==========

OSM concentrations were shown to be affected by various renal conditions including acute renal injury, urolithiasis, shockwave lithotripsy, PCNL \[[@CR9], [@CR19], [@CR20]\]. Iodinated contrast media were also shown to impact OSMs \[[@CR21]\]. Other conditions like renal colic do not increase oxidative stress \[[@CR22]\]. OSMs represent the extent of oxidative stress and may be used to compare different methods of treatment at subclinical level. They can be measured in either spontaneous urine collection or 24-h urine collection \[[@CR19]\]. Clinical usefulness of tPCNL is well documented with less pain, lower usage of pain medications and shorter hospitalization time \[[@CR23]--[@CR26]\]. However, whether tPCNL is favorable on pathophysiological level was, so far, not examined. To study this issue, we decided to measure OSM levels in urine after cPCNL and tPCNL in four consecutive days. There are many OSMs, but among most studied are CAT, total antioxidant capacity, protein sulfhydryl groups and SOD. Interestingly, only CAT and TAC significantly differed at days 3 and 4 between groups, while other two OSM were not. This fact may result from the presence of other pathological states like hiperuricosuria, local inflammation, diet, smoking habit, emotional status, which can affect one of OSMs but do not the others; however, exact cause is not known \[[@CR19], [@CR27]--[@CR29]\]. Unfortunately, due to abundance of such pathological states we were unable to control for all of them in multivariate analysis. Such analysis would require significantly more participants.

To be sure that operation itself would not influence the levels of OSM in days 3 and 4, we adopted strict exclusion criteria. Patients who required nephrostomy tube postoperatively (e.g., severe bleeding, any doubt about completeness of procedure, prolonged procedure) were excluded from the study. If such a bias would occur, it would be visible in OSM concentrations in day 2 (the day of operation). None of the OSM, hemoglobin or protein concentration in urine differed between groups on day 2.

Having the data about protein concentration and hemoglobin concentration in each urine sample, we were able to study any relationship between various groups including tubeless/classic, uni-/multitract, inter-/infracostal access but we were unable to find any significant differences. All OSM showed concentration peak (drop for TAC) at the day of operation and slow normalization in the following days. While SH and SOD were similar between tPCNL and cPCNL in days 3 and 4, CAT and TAC concentrations showed significant difference in favor of tPCNL. In other studies, we confirmed significant relationship between time of operation and oxidative stress but only for SOD concentration (day 2) \[[@CR9]\]. Such correlation was significant but weak (*r* = 0.29; *p* \< 0.05). This may also result from the fact that SOD mostly reflects amount of blood and protein in urine. Other OSMs were not significantly correlated with operation time. There are some limitations of our study that have to be mentioned. Firstly, there are no other studies regarding the sole effect of nephrostomy tube on OSM in urine. Based on our study, we know that oxidative stress is the highest just after operation and is the result of the trauma to the kidney. In the following days, oxidative stress diminishes but nephrostomy tube keeps it higher in comparison with tubeless technique (at least based on TAC and CAT activity). Secondly, this study was conducted in single tertiary care center. Future studies should include more participants from many urological departments. Thirdly, future studies should include reference (nephrostomy only) group to fully assess oxidative stress after percutaneous surgery of the kidney.

Conclusions {#Sec9}
===========

CAT showed lower and TAC showed higher concentrations after tPCNL favoring this method. Other OSM showed equivalence of both methods. Operation itself triggers the highest oxidative stress which normalize in the following days. SOD concentration in urine is highly dependent on the amount of blood and protein in samples. SOD is also significantly and positively correlated with operation time as the sole OSM. Other factors (like infra/intercostal access, accessed calyx, stone position and diameter) did not influence OSM. The best way to alleviate oxidative stress postoperatively is to perform tPCNL or maintain nephrostomy tube for as short as possible.
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